FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161036171> ?p ?o ?g. }

• W3161036171 abstract "SARS-CoV-2 belongs to the family of enveloped, single-strand RNA viruses known as Betacoronavirus in Coronaviridae, first reported late 2019 in China. It has since been circulating world-wide, causing the COVID-19 epidemic with high infectivity and fatality rates. As of the beginning of April 2021, pandemic SARS-CoV-2 has infected more than 130 million people and led to more than 2.84 million deaths. Given the severity of the epidemic, scientists from academia and industry are rushing to identify antiviral strategies to combat the disease. There are several strategies in antiviral drugs for coronaviruses including empirical testing of known antiviral drugs, large-scale phenotypic screening of compound libraries and target-based drug discovery. To date, an increasing number of drugs have been shown to have anti-coronavirus activities in vitro and in vivo, but only remdesivir and several neutralizing antibodies have been approved by the US FDA for treating COVID-19. However, remdesivir's clinical effects are controversial and new antiviral drugs are still urgently needed. We will discuss the current status of the drug discovery efforts against COVID-19 and potential future directions. With the ever-increasing movability of human population and globalization of world economy, emerging and reemerging viral infectious diseases seriously threaten public health. Particularly the past and ongoing outbreaks of coronaviruses cause respiratory, enteric, hepatic and neurological diseases in infected animals and human (Woo et al., 2009). The human coronavirus (HCoV) strains (HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1) usually cause common cold with mild, self-limiting upper respiratory tract infections. By contrast, the emergence of three deadly human betacoronaviruses, middle east respiratory syndrome coronavirus (MERS) (Zaki et al., 2012), severe acute respiratory syndrome coronavirus (SARS-CoV) (Lee et al., 2003), the SARS-CoV-2 (Jin et al., 2020a) highlight the need to identify new treatment strategies for viral infections. SARS-CoV-2 is the etiological agent of COVID-19 disease named by World Health Organization (WHO) (Zhu N. et al., 2020). This disease manifests as either an asymptomatic infection or a mild to severe pneumonia. This pandemic disease causes extent morbidity and mortality in the whole world, especially regions out of China. Similar to SARS and MERS, the SARS CoV-2 genome encodes four structural proteins, sixteen non-structural proteins (nsp) and accessory proteins. The structural proteins include spike (S), envelope (E), membrane (M), nucleoprotein (N). The spike glycoprotein directly recognizes and engages cellular receptors during viral entry. The four non-structural proteins including papain-like protease (PLpro), 3-chymotrypsin-like protease (3CLpro), helicase, and RNA-dependent RNA polymerase (RdRp) are key enzymes involved in viral transcription and replication. The spike and the four key enzymes were considered attractive targets to develop antiviral agents (Zumla et al., 2016). The catalytic sites of the four enzymes of SARS-CoV2 share high similarities with SARS CoV and MERS in genomic sequences (Morse et al., 2020). Besides, the structures of the key drug-binding pockets are highly conserved among the three coronaviruses (Morse et al., 2020). Therefore, it follows naturally that existing anti-SARS-CoV and anti-MERS drugs targeting these enzymes can be repurposed for SARS-CoV-2. Based on previous studies in SARS-CoV and MERS-CoV, it is anticipated a number of therapeutics can be used to control or prevent emerging infectious disease COVID-19 (Li and de Clercq, 2020; Wang et al., 2020c; Ita, 2021), these include small-molecule drugs, peptides, and monoclonal antibodies. Given the urgency of the SARS-CoV-2 outbreak, here we discuss the discovery and development of new therapeutics for SARS-CoV-2 infection based on the strategies from which the new drugs are derived." @default.
• W3161036171 created "2021-05-24" @default.
• W3161036171 creator A5015878775 @default.
• W3161036171 creator A5056736081 @default.
• W3161036171 date "2021-05-13" @default.
• W3161036171 modified "2023-10-18" @default.
• W3161036171 title "Current Strategies of Antiviral Drug Discovery for COVID-19" @default.
• W3161036171 cites W1965936780 @default.
• W3161036171 cites W1966238900 @default.
• W3161036171 cites W1977475475 @default.
• W3161036171 cites W1987665528 @default.
• W3161036171 cites W1991249533 @default.
• W3161036171 cites W2018534682 @default.
• W3161036171 cites W2074095102 @default.
• W3161036171 cites W2088239064 @default.
• W3161036171 cites W2102229939 @default.
• W3161036171 cites W2104930292 @default.
• W3161036171 cites W2131262274 @default.
• W3161036171 cites W2165157662 @default.
• W3161036171 cites W2166867592 @default.
• W3161036171 cites W2170017134 @default.
• W3161036171 cites W2171353131 @default.
• W3161036171 cites W2255243349 @default.
• W3161036171 cites W2292021561 @default.
• W3161036171 cites W2296414617 @default.
• W3161036171 cites W2324097903 @default.
• W3161036171 cites W2410066853 @default.
• W3161036171 cites W2509449660 @default.
• W3161036171 cites W2563411735 @default.
• W3161036171 cites W2581823548 @default.
• W3161036171 cites W2725497285 @default.
• W3161036171 cites W2739679816 @default.
• W3161036171 cites W2770110160 @default.
• W3161036171 cites W2778062090 @default.
• W3161036171 cites W2789890016 @default.
• W3161036171 cites W2806834952 @default.
• W3161036171 cites W2896387299 @default.
• W3161036171 cites W2926839160 @default.
• W3161036171 cites W2965563959 @default.
• W3161036171 cites W2991491848 @default.
• W3161036171 cites W2999455090 @default.
• W3161036171 cites W3001118548 @default.
• W3161036171 cites W3001897055 @default.
• W3161036171 cites W3003465021 @default.
• W3161036171 cites W3004280078 @default.
• W3161036171 cites W3004894342 @default.
• W3161036171 cites W3005212621 @default.
• W3161036171 cites W3005403371 @default.
• W3161036171 cites W3005527412 @default.
• W3161036171 cites W3005905966 @default.
• W3161036171 cites W3006116465 @default.
• W3161036171 cites W3006718791 @default.
• W3161036171 cites W3007643904 @default.
• W3161036171 cites W3007924766 @default.
• W3161036171 cites W3008142620 @default.
• W3161036171 cites W3009314935 @default.
• W3161036171 cites W3009655369 @default.
• W3161036171 cites W3009912996 @default.
• W3161036171 cites W3010630871 @default.
• W3161036171 cites W3011072970 @default.
• W3161036171 cites W3012379316 @default.
• W3161036171 cites W3012492786 @default.
• W3161036171 cites W3012588029 @default.
• W3161036171 cites W3012994592 @default.
• W3161036171 cites W3013334176 @default.
• W3161036171 cites W3013855790 @default.
• W3161036171 cites W3014504912 @default.
• W3161036171 cites W3014656992 @default.
• W3161036171 cites W3014708904 @default.
• W3161036171 cites W3014962324 @default.
• W3161036171 cites W3015190630 @default.
• W3161036171 cites W3015490759 @default.
• W3161036171 cites W3015608194 @default.
• W3161036171 cites W3015613878 @default.
• W3161036171 cites W3015807479 @default.
• W3161036171 cites W3016661132 @default.
• W3161036171 cites W3017331996 @default.
• W3161036171 cites W3018360824 @default.
• W3161036171 cites W3020239101 @default.
• W3161036171 cites W3020300207 @default.
• W3161036171 cites W3021621689 @default.
• W3161036171 cites W3022285953 @default.
• W3161036171 cites W3023464695 @default.
• W3161036171 cites W3023698680 @default.
• W3161036171 cites W3023724901 @default.
• W3161036171 cites W3024602798 @default.
• W3161036171 cites W3025226065 @default.
• W3161036171 cites W3025559601 @default.
• W3161036171 cites W3025744748 @default.
• W3161036171 cites W3025987322 @default.
• W3161036171 cites W3027118920 @default.
• W3161036171 cites W3028922935 @default.
• W3161036171 cites W3029682964 @default.
• W3161036171 cites W3029848232 @default.
• W3161036171 cites W3032255042 @default.
• W3161036171 cites W3032677067 @default.
• W3161036171 cites W3032915827 @default.
• W3161036171 cites W3033909911 @default.
• W3161036171 cites W3034202401 @default.
• W3161036171 cites W3036529319 @default.

• next